Document is current

Article History

Received: 18 March 2022

Accepted: 8 June 2022

First Online: 21 July 2022

Declarations

:

: AT has received personal fees from Eli Lilly, personal fees from Taiho Pharmaceutical, grants and personal fees from Ono Pharmaceutical, personal fees from Chugai Pharma, grants and personal fees from Takeda, personal fees from Merck Serono, grants from Merck Sharp & Dohme, grants from Eisai, grants from Bayer Yakuhin, grants from Bristol Myers Squibb, all outside the submitted work. HY has received honoraria from Taiho Pharmaceutical, Chugai Pharma, Eli Lilly Japan, Merk Biopharma, Yakult Honsha, Bayer Yakuhin, and Takeda Pharmaceutical, all outside the submitted work. TE has received grants from MSD, Novartis, Ono, Astellas, Astellas Amgen Biopharma, BeiGene, Ignyta, Array BioPharma, Merck Serono, and Dainippon Sumitomo as well as honoraria from Chugai, all outside the submitted work. TT received personal fees from Daiichi Sankyo Co., Ltd. as well as grants from Takeda Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., BeiGene Co., Ltd., and Ono Pharmaceutical Co., Ltd., all outside the submitted work. EB received research funding from Ono, Merck Sharp & Dohme, Eisai, Taiho, Bayer, Eli Lilly, Chugai, and Daichi-Sankyo as well as honoraria for lecture and advisory roles from Ono, Chugai, Taiho, Tsumura, Eli Lilly, Merck Sharp & Dohme, Sanofi, Miyarisan, Daiichi-Sankyo, AstraZeneca, Astellas, all outside the submitted work. TD received personal fees from Sysmex, Ono Pharmaceutical, and Sawai, all outside the submitted work. HU received research funding for his institution from Chugai and Takeda pharmaceutical companies, both outside the submitted work. TI, HS, HY, HU, MT, TS, HO, YT, AT, MG MSa, SO, KS, TF, MSh, KN, and YS declare no competing interests.